Lipid Nanoparticles (LNPs) CDMO Market Size, Share and Growth Analysis 2025 to 2034
Segmentation Of The Lipid Nanoparticles (LNPs) CDMO Market
Global Lipid Nanoparticles (LNPs) CDMO Market, by Product,
- mRNA
- Plasmid DNA (pDNA)
- siRNA
- saRNA
- microRNA
- Others
Global Lipid Nanoparticles (LNPs) CDMO Market, by Scale of Operation,
- Preclinical Scale Operations
- Clinical Scale Operations
- Commercial Scale Operations
Global Lipid Nanoparticles (LNPs) CDMO Market, by By End-Users,
- Pharmaceutical Companies
- Academic Research Institute
- Diagnostic Laboratories
Global Lipid Nanoparticles (LNPs) CDMO Market, by Region,
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Lipid Nanoparticles (LNPs) CDMO Market, by Country,
- U.S.
- Canada
Europe Lipid Nanoparticles (LNPs) CDMO Market, by Country,
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market, by Country,
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Lipid Nanoparticles (LNPs) CDMO Market, by Country,
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market, by Country,
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Landscape
- Company Overview
- Financial Performance
- Key Development
- Latest Strategic Developments
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs) Snapshot
Chapter 4. Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs) Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis: Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
4.9. Clinical Trial/Pipeline Analysis
4.10. Application of mRNA Beyond COVID 19 Vaccine
Chapter 5. Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. By Products, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. mRNA
5.2.2. Plasmid DNA (pDNA)
5.2.3. siRNA
5.2.4. saRNA
5.2.5. microRNA
5.2.6. Other Products
Chapter 6. Market Segmentation 2: By End-Users Estimates & Trend Analysis
6.1. By End-Users & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-Users:
6.2.1. Pharmaceutical Companies
6.2.2. Academic Research Institute
6.2.3. Diagnostic Laboratory
Chapter 7. Market Segmentation 3: By Scale of Operation Estimates & Trend Analysis
7.1. By Scale of Operation & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Scale of Operation:
7.2.1. Preclinical
7.2.2. Clinical
7.2.3. Commercial
Chapter 8. Lipid Nanoparticles (LNPs) CDMO Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
8.1.2. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By End-Users, 2021-2034
8.1.3. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2021-2034
8.1.4. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, 2021-2034
8.2.2. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, 2021-2034
8.2.3. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, 2021-2034
8.2.4. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, 2021-2034
8.3.2. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, 2021-2034
8.3.3. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, 2021-2034
8.3.4. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.4.2. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, (US$ Million) 2021-2034
8.4.3. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
8.4.4. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.5.2. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, (US$ Million) 2021-2034
8.5.3. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
8.5.4. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Corden Pharma GmbH
9.2.2. eTheRNA
9.2.3. Curapath (Polypeptide Therapeutic Solutions (PTS))
9.2.4. FUJIFILM Corporation
9.2.5. ST Pharm Co Ltd
9.2.6. Exelead (Merck KGaA)
9.2.7. Avanti Polar Lipids, Inc. (Croda International Plc.)
9.2.8. Emergent CDMO
9.2.9. Esco Aster Pte Ltd
9.2.10.Vernal Biosciences
9.2.11.Recipharm AB
9.2.12.Ardena Holding NV
9.2.13.Curia Global, Inc.
9.2.14.Helix Biotech
9.2.15.Phosphorex Inc
9.2.16.Polymun Scientific Immunbiologische Forschung GmbH
9.2.17.Lonza Group AG
9.2.18.Evonik
9.2.19.Samsung Biologics
9.2.20.Catalent, Inc
9.2.21.Genevant Sciences
9.2.22. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Lipid Nanoparticles (LNPs) CDMO Market Size is valued at USD 205.4 Million in 2024 and is predicted to reach USD 803.6 Million by the year 2034
Lipid Nanoparticles (LNPs) CDMO Market is expected to grow at a 14.8% CAGR during the forecast period for 2025 to 2034
Corden Pharma GmbH, eTheRNA, Polypeptide Therapeutic Solutions(PTS), FUJIFILM Corporation, ST Pharm Co Ltd, Exalead (Merck KGaA), Others
product, the scale of operation, end-users, and region are the key segments of the Lipid Nanoparticles (LNPs) CDMO Market.
North America is leading the Lipid Nanoparticles (LNPs) CDMO Market.